Sign in

Brian Tanquilot

Senior Equity Research Analyst at Jefferies

Brian Tanquilut is a Senior Equity Research Analyst at Jefferies, specializing in healthcare services and healthcare IT, with coverage spanning over 65 companies including Surgery Partners Inc., Amedisys, and other major players in the US and Canadian healthcare sectors. He is recognized for his strong analyst performance, holding a 53% to 61% success rate and average returns between 2.3% and 11.7%, and has issued over 750 ratings, with the majority being Buy recommendations and a notable best call return of 257.7%. Since joining Jefferies, Tanquilut has established himself as a top-ranked analyst, previously holding finance and analyst roles at Asia United Bank Corp. and earning an MBA in Finance between 2001 and 2003. He holds FINRA securities licenses and is frequently referenced for his expertise in value-based healthcare transformation.

Brian Tanquilot's questions to BrightSpring Health Services (BTSG) leadership

Question · Q3 2025

Brian Tanquilot asked about the cadence of upcoming patent expirations in BrightSpring's portfolio and the margin ramp dynamics for new generic launches. He also inquired about the cause of the delay in the community living divestiture and what to look for regarding its closure.

Answer

CEO Jon Rousseau stated that the publicly available information on numerous brand-to-generic conversions over the next couple of years, including a significant one at the end of Q1 next year, remains consistent. He expects similar overall dynamics in these conversions as experienced historically. Regarding the community living divestiture, Mr. Rousseau explained that the delay is due to the time these processes can take, exacerbated by the recent government shutdown. He remains optimistic for a Q1 close, noting that the buyer is working through a handful of markets with the FTC, which is ongoing and straightforward.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts